Corpus Intelligence IC Memo — CEDARS-SINAI MEDICAL CENTER 2026-04-26 05:03 UTC
IC Memo — CEDARS-SINAI MEDICAL CENTER
Investment Committee Memorandum | CA | 908 beds | Grade B | EBITDA uplift $288.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CEDARS-SINAI MEDICAL CENTER

CCN 050625 | LOS ANGELES, CA | 908 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

CEDARS-SINAI MEDICAL CENTER is a 908-bed large academic medical center in LOS ANGELES, CA with $3.92B in net patient revenue and a -5.5% operating margin. The hospital serves a payer mix of 38.5% Medicare, 5.6% Medicaid, and 55.9% commercial.

Thesis: Undervalued. Our ML models identify $288.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.5% to 1.8% (+736bps).

Net Revenue HCRIS$3.92B
Current EBITDA COMPUTED$-216.5M
Operating Margin COMPUTED-5.5%
Occupancy HCRIS92.2%
Revenue / Bed COMPUTED$4.3M
Net-to-Gross HCRIS15.1%
Distress Probability ML36.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
22
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -5.5% places it below the state median. Among 22 size-comparable peers (454-1816 beds), the median margin is 0.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (454-1816), prioritizing same-state peers. 22 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CEDARS-SINAI MEDICAL CENTER (Target)CA908$3.92B-5.5%
STANFORD HEALTH CARECA657$6.76B3.7%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
SANTA CLARA VALLEY MEDICAL CENCA805$2.55B-29.4%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
COMMUNITY REGIONAL MEDICAL CENCA783$1.47B-10.0%
KFH - FONTANACA654$1.47B6.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $288.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$82.4M+210bp18mo
Cost to Collect4.5%2.5%$78.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$77.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$47.7M+122bp9mo
Clean Claim Rate88.0%96.0%$2.5M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$82.4M
Cost to Collect
$78.5M
Denial Rate Reduction
$77.7M
A/R Days Reduction
$47.7M
Clean Claim Rate
$2.5M
Total EBITDA Uplift$288.7M
Current EBITDA$-216.5M
+ RCM Uplift+$288.7M
Pro Forma EBITDA$72.2M
Current Margin-5.5%
Pro Forma Margin1.8%
WC Released (1x)$150.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-333.1M$1.46B0.00x-100.0%
Base (11x exit)10.0x11.0x$-333.1M$1.50B0.00x-100.0%
Bull Case9.0x11.0x$-299.8M$2.34B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-299.8M$2.47B0.00x-100.0%
Bear Case11.0x10.0x$-366.5M$123.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-366.5M$16.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 22 hospitals with 454-1816 beds
  • Same-state prioritization (n=23)
  • Comp margins: P25=-10.0% / P50=0.1% / P75=6.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.